empagliflozin glp-1 Still only thinking βA1cβ in diabetes? You're missing the bigger picture. Patients with diabetes + ASCVD need more than glycemic control. They need cardiovascular protection. π SGLT2 inhibitors π receptor agonists Empagliflozin Meets Primary End Point
Pay in 4 interest-free payments of $5.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 10 - Aug 15


























